SBSarah Samuel Boyd

Sarah Samuel Boyd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah Samuel Boyd has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Time Until Procedural Intervention in Female Bladder Pain Syndrome at a Tertiary Referral Center in the United States

    by Noor Banihashem Ahmad, Shreela Natarajan, Allen Kunselman, Christina Stetter, Sarah S. Boyd

    Introduction and Hypothesis: Female bladder pain syndrome (FBPS) is a chronic condition characterized by bladder pain, urgency, and frequency that significantly impacts quality of life. Management includes nonsurgical and procedural therapies. Our objective was to evaluate the time from FBPS diagnosis to procedural intervention and identify predictors of intervention. Methods: A retrospective cohort study identified women with FBPS from 2013 to 2023 using ICD-10 codes at a single tertiary care center in the United States. Interventions were categorized per the 2022 AUA guideline, including behavioral/non-pharmacologic therapies, medications, intravesical instillations, procedures, and major surgeries. Kaplan–Meier analysis estimated time to first procedural intervention, and Cox proportional hazards models identified factors associated with intervention. Results: Among 149 patients, 111 (74.5%) underwent at least one bladder-directed procedural intervention, with a median time to first procedure of 1.08 years. The most common intervention was cystoscopy with hydrodistension ( N = 83, 55.7%), followed by intravesical instillations (53, 35.6%). Image-guided nerve blocks (11, 7.4%) and onabotulinumtoxinA injections (5, 3.4%) were less frequent. Among those undergoing procedures, 84 (75.7%) required repeat interventions. On multivariable analysis, stress urinary incontinence (HR 2.02, p = 0.05) and tobacco use (HR 1.86, p = 0.03) were associated with increased hazard, while partnered relationship status was associated with reduced hazard (HR 0.62, p = 0.05). Conclusion: Most patients with FBPS underwent procedural intervention by 1.08 years from diagnosis, most commonly cystoscopy with hydrodistension. Stress urinary incontinence and tobacco use were significant predictors. These findings highlight the importance of individualized management and early identification of patients likely to require procedural therapy.

  • Open Access

    Postoperative Pain and Opioid Use in Urogynecology Patients

    by Laura DiVirgilio, Jaime B. Long, Sarah S. Boyd

    Opioid use disorder remains a leading national cause of mortality. Physician opioid prescribing contributes to this crisis. In urogynecology, most of these prescriptions are aimed at addressing postoperative pain. This expert review examines the factors that contribute to postoperative pain and opioid use in urogynecologic patients. We discuss patient characteristics, physician interventions and alternative therapies that may influence postoperative pain and opioid use. By identifying patients at higher risk for postoperative pain and opioid use and utilizing evidence-based strategies to mitigate postoperative pain, physicians caring for urogynecology patients can both reduce postoperative opioid use while still providing adequate patient pain control.

  • Effect of Body Mass Index on Complications After Vaginal and Laparoscopic Apical Prolapse Surgery

    by Sarah S. Boyd, Dominique Exume, Jaime B. Long, Christina Stetter, Allen Kunselman

    Introduction and Hypothesis Obesity is increasing worldwide, and data are limited on how body mass index (BMI) affects surgical risk in pelvic organ prolapse. This study is aimed at evaluating the impact of obesity on outcomes after apical pelvic organ prolapse surgery. We hypothesize that obese patients have higher rates of postoperative complications. Methods This is a retrospective cohort study using the American College of Surgeons National Surgical Quality Improvement Program database from 2014 to 2018. Current Procedural Terminology codes identified subjects aged 18–89 who underwent apical prolapse repair, including vaginal colpopexy and laparoscopic or robotic sacrocolpopexy. Minor and major complications were analyzed using the World Health Organization BMI category. Regression analysis was performed to adjust for confounders. Results The total cohort was 24,718 with 15,137 vaginal colpopexy and 9,581 laparoscopic/robotic sacrocolpopexy. The average age was 60.1, 76.5% were white, 24.2% were American Society of Anesthesiologists (ASA) class 3 or 4, and 44.7% had a major medical comorbidity. Eight hundred and eighty-five patients (5.4%) experienced a minor complication, 324 (2.0%) a major complication, and 1,167 (7.2%) any complication. There was no difference in any, major, or minor complication by BMI and this persisted after adjusting for age, race, ASA class, smoking, and surgical approach. Conclusions There is no difference in complication rates after apical prolapse surgery by BMI regardless of age, race, ASA class, smoking use, and surgical approach. Patients and surgeons should be reassured that minimally invasive apical prolapse surgery is safe, with low complication rates. Randomized controlled trials are needed to verify these findings.


  • Open Access

    Liberal vs. restricted opioid prescribing following midurethral sling dataset

    by Brianne M. Morgan, Jaime B. Long, Sarah S. Boyd, Matthew F. Davies, Allen R. Kunselman, Christy M. Stetter, Michael H. Andreae

  • Incidence of Midurethral Sling Revision or Removal by Its Timing With Prolapse Surgery

    by Sarah Samuel Boyd, Jaime B. Long, Edeanya Agbese, Douglas Leslie

    Objective: The aim of the study was to evaluate incidence of midurethral sling removal/revision based on timing with surgery for pelvic organ prolapse. Methods: This was a retrospective cohort study of women who underwent midurethral sling placement in a claims-based database of women 65 years or older. Three groups were identified using the Current Procedural Terminology codes: (1) isolated sling, (2) concomitant sling, and (3) prolapse surgery and staged sling after prolapse surgery. In the staged group, placement of sling was identified within 18 months after index prolapse surgery. Fascial grafts were excluded. Sling removal/revision was identified across 3 years after sling surgery using Current Procedural Terminology code 57287. Rates of sling removal/revision were calculated by group. Comparisons were made using the χ 2 test and analysis of variance. Cumulative incidence of removal/revision was evaluated using the Kaplan-Meier curves. Cox proportional hazards was performed to evaluate factors influencing removal/revision. Results: We identified 39,381 isolated MUSs, 25,389 concomitant, and 886 staged. The rate of sling removal/revision was 3.52%. Rates of removal/revision differed between groups (7% staged vs 3.94% concomitant vs 3.17% isolated sling, P < 0.001). Compared with the staged group, the rate of removal/revision was lower in the isolated sling group (relative risk, 0.4550; 95% confidence interval [CI], 0.358–0.568) and the concomitant group (relative risk, 0.5666; 95% CI, 0.4450–0.7287). After adjusting for patient characteristics, sling revision or removal remained significantly less in the isolated MUS (hazard ratio, 0.50; 95% CI, 0.39–0.65) and concomitant (odds ratio, 0.55; 95% CI, 0.43–0.71) groups. Conclusions: Sling removal/revision is higher when it is staged after prolapse surgery compared with isolated and concomitant placement. Future studies are needed to confirm these findings in a controlled population.


  • Open Access

    Opioid Prescribing and Utilization Following Isolated Mid-Urethral Sling

    by Alex J. Knutson, Brianne M. Morgan, Rehan Feroz, Sarah S. Boyd, Christy M. Stetter, Allen R. Kunselman, Jaime B. Long

    Introduction: Overprescribing by providers is a leading contributor to the opioid crisis. Despite available information regarding the role that physician prescribing plays in the community availability of opioids, guidelines for the management of acute pain remain sparse. This project aims to evaluate opioid prescribing, opioid usage patterns, and postoperative pain control in patients undergoing isolated mid-urethral sling (MUS) placement. Methods: Patients who underwent isolated MUS placement from March 19, 2019 through March 19, 2020 were contacted by telephone in May 2020 and asked a series of questions examining opioid usage, postoperative pain, what they did with unused opioids, and whether they had received education on disposal techniques. A chart review was utilized to determine the amount of opioid prescribed, the presence of any operative complications, and medical and demographic characteristics of subjects. Results: A total of 53 subjects met inclusion criteria, of which 31 participated in a phone interview. Of the 53 subjects, 54.7% received a postoperative opioid prescription, and all but two of these subjects filled their prescription. Of the interviewed subjects, only 66.6% who filled a prescription reported using opioids Fifty percent (n=6) of patients that required oxycodone reported use of four tablets (30 morphine milligram equivalents (MMEs)) or less and used for 1-2 days postoperatively. No patient reported using opioids beyond five days. Only 22.2% reported receiving instruction on opioid disposal, and 16.7% returned unused opioids to a disposal center. 87.1% of subjects rated postoperative pain as “better” or “much better” than expected. Conclusion: Patients undergoing isolated MUS placement require limited amounts of postoperative opioids, if any are needed at all, to achieve satisfactory pain control. Excess prescribed opioids, along with inadequate patient education on proper disposal techniques, may contribute towards opioids that are at risk of diversion for nonmedical use.

  • Pelvic Organ Prolapse Severity and Genital Hiatus Size With Long-Term Pessary Use

    by Sarah S. Boyd, Divya Bs Subramanian, Katie Propst, David O’SUllivan, Paul Tulikangas

    Objectives: To evaluate the association between pessary use more than 1 year and change in prolapse severity. Methods: This is a secondary analysis of a previously published randomized controlled trial of women undergoing office management of pessaries for management of symptomatic pelvic organ prolapse and incontinence. Primary outcome was change in pelvic organ prolapse quantification measurement genital hiatus (GH). Secondary outcomes included change in prolapse stage, type of pessary, size of pessary, number of pessary changes, and duration of use. Baseline data were collected from the earliest documented examination within the hospital record before pessary placement and compared with their final study visit. Demographics were analyzed using descriptive statistics. Student t test and Mann-Whitney tests were used for categorical comparisons. Pearson and Spearman correlation coefficients were used to evaluate change over time. Results: The cohort was 132 predominantly non-Hispanic White (75%) women with symptomatic prolapse >stage 2 (70.5%). All were postmenopausal. Median duration of pessary use was 39.5 months (interquartile range, 17–64.5 months). Genital hiatus ( P = 0.014) and prolapse stage ( P = 0.001) decreased as duration of pessary use increased. Those with baseline stages ≥3 had a significant decrease in GH as duration of pessary use increased compared with stages P < 0.001). There was no difference in change in GH when comparing women with baseline GH less than 3 to 3 cm or greater. Conclusions: Pessary use by women with pelvic organ prolapse causes a change in vaginal anatomy over time as seen by decreasing stage and point GH.